Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
2021 · Breast Cancer Research · 150 citations
https://doi.org/10.1186/s13058-021-01492-x
C
Christoph Tinchon
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
72
Papers
1.7K
Citations
15
h-index
20
i10-index
Christoph Tinchon is an academic researcher from LKH Hochsteiermark. The author has contributed to research in topics: Cancer Treatment and Pharmacology & Advanced Breast Cancer Therapies & Multiple Myeloma Research and Treatments. The author has an h-index of 15, co-authored 62 publications.
Papers by this author
worksAzacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
2014 · Annals of Hematology · 93 citations
https://doi.org/10.1007/s00277-014-2126-9
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT
2020 · The Breast · 20 citations
https://doi.org/10.1016/j.breast.2020.01.035
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group
2022 · ESMO Open · 19 citations
https://doi.org/10.1016/j.esmoop.2022.100747
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat